We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?
Read MoreHide Full Article
Key Takeaways
Regeneron's shares surged 27.4% in a month, driven by strong third-quarter results and product demand.
Eylea HD sales jumped 62% to $699 million, helping offset declining Eylea sales amid rising competition.
Dupixent growth, oncology expansion and a promising pipeline strengthen long-term growth outlook.
The going has been strong for Regeneron Pharmaceuticals (REGN - Free Report) over the past month. Shares of this biotech giant have surged 27.4% over the said time frame, outpacing the industry’s growth of 10.9%. The stock has outperformed the sector and the S&P 500 Index during the period.
REGN’s robust rally has been driven by strong third-quarter results, which can be attributed to solid demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales.
REGN Outperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
Against this backdrop, a closer evaluation of the company’s strengths and weaknesses can help assess its attractiveness as an investment opportunity.
REGN’s Eylea HD Gains Traction as Eylea Sales Decline
While lead drug Eylea continues to face headwinds, Eylea HD is gaining traction, supported by steady label expansions.
Eylea is an anti-VEGF therapy approved across multiple ophthalmology indications. Declining sales of this drug continue to pressure the company’s overall revenues.
Competitive pressures have increased, particularly from Roche's Vabysmo, which targets both angiopoietin-2 (Ang-2) and VEGF-A pathways and has gained traction in the retinal disease market. Additional biosimilar launches could further weigh on Eylea sales.
To combat the decline in Eylea sales, Regeneron introduced Eylea HD, a higher-dose formulation of Eylea designed to improve durability and extend dosing intervals.
Eylea HD sales in the United States surged 62% year over year to $699 million in the third quarter of 2026, driven by strong uptake following FDA label expansions and growing physician confidence in its differentiated profile and flexible dosing regimen.
REGN expects the prefilled syringe to receive regulatory approval before year-end, which could further drive product adoption.
In April 2026, the FDA approved the extension of dosing intervals for Eylea HD to up to every 20 weeks (5 months) for patients with wet age-related macular degeneration and diabetic macular edema following a year of successful response based on visual and anatomic outcomes.
Eylea and Eylea HD were co-developed with Bayer BAYRY.
Regeneron records net product sales in the United States, while Bayer records sales outside the country. It expects a further decline in Eylea sales in the second half of 2026 due to ongoing conversion to Eylea HD and increasing competition as multiple biosimilar versions enter the U.S. market.
Strong Dupixent Sales Fuel REGN Profits
REGN’s top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi SNY records global net product sales of Dupixent.
Dupixent continues to lead the biologic market across its major indications, including atopic dermatitis, asthma, nasal polyps and eosinophilic esophagitis, supported by its best-in-class efficacy and safety profile. Uptake is also gaining momentum across newer indications, including COPD, prurigo nodularis, chronic spontaneous urticaria, bullous pemphigoid and allergic fungal rhinosinusitis, with continued growth in new-to-brand prescriptions.
Ongoing label expansions for Dupixent remain a key contributor to revenue visibility and profitability.
In October 2026, Regeneron expanded its longstanding Sanofi alliance to include four next-generation, long-acting antibodies targeting inflammatory pathways associated with Dupixent. Under the agreement, Regeneron received a $1 billion upfront payment and is eligible for up to $7 billion in additional development, regulatory and sales milestones.
Regeneron Expands and Strengthens Its Oncology Portfolio
Regeneron’s oncology franchise is anchored by its PD-1 inhibitor Libtayo (cemiplimab-rwlc), which is approved for use in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma (CSCC) and advanced non-small cell lung cancer (NSCLC).
Libtayo sales continue to be robust, driven by strength across non-melanoma skin cancers and NSCLC. The recent adjuvant CSCC launch is fueling growth. Efforts to improve patient experience through extended dosing intervals and shorter infusion times across approved indications are expected to further support adoption. Continued market-share gains in lung cancer and increased uptake in adjuvant CSCC are likely to drive Libtayo's growth.
Regeneron continues to expand its rare disease portfolio, targeting conditions with significant unmet medical needs. Evkeeza is gaining traction in its sixth year on the market. The company has also broadened its portfolio with the recent launches of Otarmeni for genetic hearing loss and Pasatru for fibrodysplasia ossificans progressiva. Early commercial progress for both products is encouraging.
Regeneron also has a deep pipeline of promising candidates, and additional drug approvals are expected to support the top line.
In neurology, Regeneron is preparing for the launch of cemdisiran for generalized myasthenia gravis, with an FDA decision expected later in November. The candidate offers significant commercial potential, supported by its novel siRNA mechanism, rapid onset of action, durable efficacy without the waning treatment effect seen with some approved therapies and convenient once-quarterly subcutaneous dosing.
REGN: Valuation & Estimates
Going by the price/earnings ratio, shares currently trade at 13.29X forward earnings, lower than its mean of 19.67X and the large-cap pharma industry’s value of 19.82X.
Image Source: Zacks Investment Research
The bottom-line estimate for 2026 has moved north over the past 30 days to $67.45 and the same for 2027 has jumped to $72.94.
Image Source: Zacks Investment Research
Invest in Regeneron Stock
REGN is among the largest biotechnology companies in the sector and is widely regarded as a safe-haven investment for biotech-focused investors.
Ongoing label expansions for Dupixent continue to drive strong sales growth and contribute meaningfully to profitability. At the same time, the strong uptake of Eylea HD has enabled Regeneron to mitigate the impact of declining sales of Eylea amid rising competition.
Progress across its oncology portfolio should support greater diversification of revenues and reduce reliance on any single franchise. The recent pipeline momentum and favorable regulatory developments have improved the outlook.
Its deep pipeline, including the potential launch of cemdisiran for generalized myasthenia gravis, provides additional growth opportunities.
Moreover, favorable earnings estimate revisions and an attractive valuation, with shares trading below historical and industry averages, strengthen the investment case. Given its diversified growth drivers, promising pipeline and favorable earnings outlook, we recommend the stock to prospective investors.
View the Zacks #1 Rank List
Image: Bigstock
REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?
Key Takeaways
The going has been strong for Regeneron Pharmaceuticals (REGN - Free Report) over the past month. Shares of this biotech giant have surged 27.4% over the said time frame, outpacing the industry’s growth of 10.9%. The stock has outperformed the sector and the S&P 500 Index during the period.
REGN’s robust rally has been driven by strong third-quarter results, which can be attributed to solid demand for Eylea HD (higher dose of Eylea) and higher profit-sharing from Dupixent that helped the company mitigate the decline in Eylea sales.
REGN Outperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
Against this backdrop, a closer evaluation of the company’s strengths and weaknesses can help assess its attractiveness as an investment opportunity.
REGN’s Eylea HD Gains Traction as Eylea Sales Decline
While lead drug Eylea continues to face headwinds, Eylea HD is gaining traction, supported by steady label expansions.
Eylea is an anti-VEGF therapy approved across multiple ophthalmology indications. Declining sales of this drug continue to pressure the company’s overall revenues.
Competitive pressures have increased, particularly from Roche's Vabysmo, which targets both angiopoietin-2 (Ang-2) and VEGF-A pathways and has gained traction in the retinal disease market. Additional biosimilar launches could further weigh on Eylea sales.
To combat the decline in Eylea sales, Regeneron introduced Eylea HD, a higher-dose formulation of Eylea designed to improve durability and extend dosing intervals.
Eylea HD sales in the United States surged 62% year over year to $699 million in the third quarter of 2026, driven by strong uptake following FDA label expansions and growing physician confidence in its differentiated profile and flexible dosing regimen.
REGN expects the prefilled syringe to receive regulatory approval before year-end, which could further drive product adoption.
In April 2026, the FDA approved the extension of dosing intervals for Eylea HD to up to every 20 weeks (5 months) for patients with wet age-related macular degeneration and diabetic macular edema following a year of successful response based on visual and anatomic outcomes.
Eylea and Eylea HD were co-developed with Bayer BAYRY.
Regeneron records net product sales in the United States, while Bayer records sales outside the country. It expects a further decline in Eylea sales in the second half of 2026 due to ongoing conversion to Eylea HD and increasing competition as multiple biosimilar versions enter the U.S. market.
Strong Dupixent Sales Fuel REGN Profits
REGN’s top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi SNY records global net product sales of Dupixent.
Dupixent continues to lead the biologic market across its major indications, including atopic dermatitis, asthma, nasal polyps and eosinophilic esophagitis, supported by its best-in-class efficacy and safety profile. Uptake is also gaining momentum across newer indications, including COPD, prurigo nodularis, chronic spontaneous urticaria, bullous pemphigoid and allergic fungal rhinosinusitis, with continued growth in new-to-brand prescriptions.
Ongoing label expansions for Dupixent remain a key contributor to revenue visibility and profitability.
In October 2026, Regeneron expanded its longstanding Sanofi alliance to include four next-generation, long-acting antibodies targeting inflammatory pathways associated with Dupixent. Under the agreement, Regeneron received a $1 billion upfront payment and is eligible for up to $7 billion in additional development, regulatory and sales milestones.
Regeneron Expands and Strengthens Its Oncology Portfolio
Regeneron’s oncology franchise is anchored by its PD-1 inhibitor Libtayo (cemiplimab-rwlc), which is approved for use in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma (CSCC) and advanced non-small cell lung cancer (NSCLC).
Libtayo sales continue to be robust, driven by strength across non-melanoma skin cancers and NSCLC. The recent adjuvant CSCC launch is fueling growth. Efforts to improve patient experience through extended dosing intervals and shorter infusion times across approved indications are expected to further support adoption. Continued market-share gains in lung cancer and increased uptake in adjuvant CSCC are likely to drive Libtayo's growth.
Regeneron continues to expand its rare disease portfolio, targeting conditions with significant unmet medical needs. Evkeeza is gaining traction in its sixth year on the market. The company has also broadened its portfolio with the recent launches of Otarmeni for genetic hearing loss and Pasatru for fibrodysplasia ossificans progressiva. Early commercial progress for both products is encouraging.
Regeneron also has a deep pipeline of promising candidates, and additional drug approvals are expected to support the top line.
In neurology, Regeneron is preparing for the launch of cemdisiran for generalized myasthenia gravis, with an FDA decision expected later in November. The candidate offers significant commercial potential, supported by its novel siRNA mechanism, rapid onset of action, durable efficacy without the waning treatment effect seen with some approved therapies and convenient once-quarterly subcutaneous dosing.
REGN: Valuation & Estimates
Going by the price/earnings ratio, shares currently trade at 13.29X forward earnings, lower than its mean of 19.67X and the large-cap pharma industry’s value of 19.82X.
Image Source: Zacks Investment Research
The bottom-line estimate for 2026 has moved north over the past 30 days to $67.45 and the same for 2027 has jumped to $72.94.
Image Source: Zacks Investment Research
Invest in Regeneron Stock
REGN is among the largest biotechnology companies in the sector and is widely regarded as a safe-haven investment for biotech-focused investors.
Ongoing label expansions for Dupixent continue to drive strong sales growth and contribute meaningfully to profitability. At the same time, the strong uptake of Eylea HD has enabled Regeneron to mitigate the impact of declining sales of Eylea amid rising competition.
Progress across its oncology portfolio should support greater diversification of revenues and reduce reliance on any single franchise. The recent pipeline momentum and favorable regulatory developments have improved the outlook.
Its deep pipeline, including the potential launch of cemdisiran for generalized myasthenia gravis, provides additional growth opportunities.
Moreover, favorable earnings estimate revisions and an attractive valuation, with shares trading below historical and industry averages, strengthen the investment case. Given its diversified growth drivers, promising pipeline and favorable earnings outlook, we recommend the stock to prospective investors.
REGN currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.